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Inflammatory myopathies: 
update on diagnosis, 




Department of Neurology, Thomas Jefferson University, Philadelphia, PA USA 
and the Neuroimmunology Unit, National and Kapodistrian University University 
of Athens Medical School, Athens, Greece
The inflammatory myopathies constitute a heterogeneous group of acquired my-
opathies that have in common the presence of endomysial inflammation. Based on 
steadily evolved clinical, histological and immunopathological features and some 
autoantibody associations, these disorders can now be classified in five character-
istic subsets: Dermatomyositis (DM) Polymyositis (PM), Necrotizing Autoimmune 
Myositis (NAM), Anti-synthetase syndrome-overlap myositis (Anti-SS-OM), and 
Inclusion-Body-Myositis (IBM). Each inflammatory myopathy subset has distinct 
immunopathogenesis, prognosis and response to immunotherapies, necessitating 
the need to correctly identify each subtype from the outset to avoid disease mim-
ics and proceed to early therapy initiation. The review presents the main clinico-
pathologic characteristics of each subset highlighting the importance of combin-
ing expertise in clinical neurological examination with muscle morphology and 
immunopathology to avoid erroneous diagnoses and therapeutic schemes. The 
main autoimmune markers related to autoreactive T cells, B cells, autoantibodies 
and cytokines are presented and the concomitant myodegenerative features seen 
in IBM muscles are pointed out. Most importantly, unsettled issues related to a 
role of autoantibodies and controversies with reference to possible triggering fac-
tors related to statins are clarified. The emerging effect SARS-CoV-2 as the cause 
of hyperCKemia and potentially NAM is addressed and practical guidelines on 
the best therapeutic approaches and concerns regarding immunotherapies during 
COVID-19 pandemic are summarized. 
Key words: dermatomyositis, polymyositis, inflammatory myopathies, COVID-19
Introduction 
Inflammatory myopathies (IM) are a heterogeneous group of acquired 
myopathies that have in common the presence of inflammation in the 
muscle. Based on distinct clinical, histological, immunopathological and 
autoantibody features, they have evolved in five distinct subsets: Derma-
tomyositis (DM), Polymyositis (PM), Necrotizing Autoimmune Myositis 
(NAM), Anti-synthetase syndrome-overlap myositis (Anti-SS-OM), and In-
clusion-Body-Myositis (IBM) 1-6. Each subset has distinct clinical features, 
pathogenesis, response to therapies and different prognosis requiring careful 
clinicopathologic correlation with expertise in muscle histopathology for a 
correct diagnosis and distinction from disease mimics. The article describes 
the main clinicopathologic and immune features of all subtypes, highlights 
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how best to avoid erroneous diagnoses, and provides prac-
tical guidelines on therapeutic approaches. 
Patients with all IM forms experience slow, subacute 
and rarely acute onset of difficulty performing tasks requir-
ing the use of proximal muscles, such as climbing steps or 
getting up from a chair; patients with IBM however, may 
present first with weakness in the distal muscles of hands 
and feet and difficulties with buttoning, typing or raising 
toes and feet. Neck-extensor and pharyngeal muscles can 
be affected in all subsets resulting in difficulty holding up 
the head (head drop) and dysphagia. In advanced cases, 
respiratory muscles can be affected. Myalgia and muscle 
tenderness may also occur, most often in anti-SS-OM; 
if myalgia is prominent, a co-existent fasciitis should be 
considered. Extramuscular manifestations may occur in 
all IM, but rarely in IBM, and include arthralgia, Ray-
naud’s phenomenon and pulmonary complications due 
to interstitial lung disease as seen in anti-SS-OM  1-6 or 
in amyopathic DM with anti-Melanoma Differentiation–
Associated protein-5 [MDA-5] antibodies 1,7.
Clinical characteristics
Dermatomyositis (DM)
DM, seen in both children and adults, presents with 
characteristic skin manifestations accompanying or pre-
ceding muscle weakness. Periorbital heliotrope (blue-pur-
ple) rash with edema, erythematous rash on face, knees, 
elbows, malleoli, neck, anterior chest (in V-sign), back 
and shoulders (in shawl sign), and knuckles with a viola-
ceous eruption (Gottron’s rash) that evolves into a scaling 
discoloration, are typical skin lesions 1-8. Dilated capillary 
loops at the base of the fingernails, irregular and thick-
ened cuticles, and cracked palmar fingertips (“mechanic’s 
hands”) are also characteristic 1-4. Subcutaneous calcifica-
tions, sometimes extruding to the surface, were common 
in our practice 20-30 years ago especially in children, as 
highlighted  8, but they are rarely seen today due to ear-
ly initiation of effective immunotherapies. When DM is 
clinically limited to the skin (amyopathic dermatomyosi-
tis), the patients seem to have normal strength, but their 
muscle is always subclinically involved; based on our 
experience with a number of such patients we have biop-
sied, their muscle shows the typical features of DM de-
scribed below but to a lesser degree 9. In children, an early 
symptom is “misery,” defined as an irritable child with 
red-flush on face, fatigue and reluctance to socialize  1-4. 
Dermatomyositis may overlap with systemic sclerosis 
and mixed connective tissue disease and requires distinc-
tion from the anti-SS-OM subset. In adults with DM there 
is a malignancy risk in up to 15% of patients, especially 
in the first 3-5 years from the disease onset 1,8. Common 
cancers are ovarian, breast, colon, melanoma, nasophar-
ynx (in Asians) and non-Hodgkin lymphoma, necessitat-
ing a thorough annual work-up the first 3 years 10. 
Polymyositis (PM) 
PM is a very rare entity. In our experience most pa-
tients referred for PM have another disease most often 
IBM, NAM, or an inflammatory dystrophy 1-3. Polymyo-
sitis does exist but remains a diagnosis of exclusion. It is 
best defined as a subacute proximal myopathy in adults 
who do not have rash, family history of neuromuscular 
disease, exposure to myotoxic drugs (d-penicillamine, 
zidovudine), involvement of facial and extraocular mus-
cles, endocrinopathy, or the clinical phenotype of IBM 1-3.
Necrotizing Autoimmune Myositis (NAM) 
NAM, also referred by some as Immune-mediated nec-
rotizing myopathty (IMNM), has now evolved as the most 
common IM subtype 1. It starts either acutely reaching its 
peak over days or weeks, or subacutely progressing steadily 
causing severe weakness and very high creatine kinase (CK) 
levels in the thousands 1. NAM may also occur after viral 
infections and in association with cancer or immune check 
point inhibitors as discussed later. Unfortunately, very often 
NAM is erroneously attributed to statins or over-diagnosed 
as a “statin-myopathy” in patients on chronic statin admin-
istration 11, even though there is no convincing evidence as 
explained later. Acute rhabdomyolysis, like seen in NAM, 
can very rarely coincide with statin initiation and may be 
the causative factor in some cases of acute-onset NAM but 
there is no convincing evidence that statins play a triggering 
role in patients who develop a subacute NAM, while tak-
ing statins for years and their myopathy continues to wors-
en even after statin withdrawal  1,11,12. Most NAM patients 
have antibodies against signal recognition particle (SRP) or 
3hydroxy3-methylglutaryl-coenzyme A reductase (HMG-
CR) 1,11,14 as discussed later. 
Anti-synthetase syndrome-Overlap Myositis (Anti-SS-OM)
Anti-SS-OM, often presents with systemic scle-
rosis-like lesions, mild-to-moderate proximal muscle 
weakness, arthritis in the form of subluxation of the in-
terphalangeal joints, “mechanic’s hands”, Raynaud phe-
nomenon, and interstitial lung disease 1. The syndrome is 
highlighted by the presence of anti-synthetase antibodies, 
primarily anti-Jo-1, hence the naming of anti-Jo-1 syn-
drome, and distinct histology with necrotizing features in 
the perimysium and perifascicular muscle fibers 1,11,16.
Inclusion Body Myositis (IBM)
This is the most common and disabling inflam-
matory myopathy above the age of 50  1-5,17,18. It starts 
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insidiously, over years, at times asymmetrically, and 
progresses steadily simulating a late-life muscular dys-
trophy or slowly progressive motor neuron disease  1-3. 
Although IBM is commonly suspected when a patient 
with presumed PM did not respond to therapy 1-3, early 
involvement of distal muscles, especially foot extensors 
and finger flexors, atrophy of the forearms and quadri-
ceps muscles, frequent falls due to quadriceps muscle 
weakness causing buckling of the knees, and mild fa-
cial muscle weakness, are clues to early clinical diag-
nosis 1-5,17-21. Axial muscles may be affected resulting in 
camptocormia or head drop. Dysphagia occurs in more 
than 50% of the patients.  1-5,17-21 IBM is a progressive 
disease leading to disability.
Diagnosis and diagnostic work-up
The diagnosis of IM is based on the combination of 
clinical history including the pattern of muscle involve-
ment and tempo of disease progression (as described 
above), combined with determination of serum muscle 
enzymes, muscle biopsy findings and at times auto-an-
tibodies. Ancillary information is provided by electro-
myography, which can be useful to exclude neurogenic 
conditions or assess disease activity. Muscle MRI with 
contrast can reveal edema and inflammation in muscle 
and fascia and is mainly useful to define and assess the 
distribution of atrophic muscles1. The usefulness of mus-
cle MRI has been excessively overestimated because the 
findings are not diagnostic for an IM and, contrary to sug-
gestions that it can help selecting the specific muscle to 
biopsy, it does not provide more than a careful neurolog-
ical examination because the surgeon can still obtain tis-
sue from a very atrophic muscle fascicle since the biopsy 
is not MRI-or CT-guided and within the seemingly viable 
muscle tissue there are long atrophic fascicles (Dalakas 
unpublished observations). 
Serum muscle enzymes
Creatine Kinase is elevated in all subtypes with active 
disease but can be normal when the disease has become 
chronic. Very high levels point to NAM, while normal 
levels from the outset can be seen in DM and anti-SS-
OM reflecting predominant pathology in the interstitial 
tissues. Aldolase may be also elevated especially if the 
fascia is involved 1,24-26. 
Muscle biopsy findings
It shows features distinct for each subset and, al-
though not always typical, remains the most reliable diag-
nostic tool when interpreted in the context of the clinical 
findings and processed in the clinician’s expert laboratory 
that performs enzyme histochemistry and immunocyto-
chemistry. Findings for each subtype are: 
a) in dermatomyositis, there is inflammation predomi-
nantly perivascularly, in the interfascicular septae or 
at the periphery of the fascicles. The muscle fibers 
undergo necrosis and phagocytosis, often in a por-
tion of a muscle fasciculus or the periphery of the 
fascicle, due to microinfarcts leading to hypoperfu-
sion and perifascicular atrophy  1-5,25. Perifascicular 
atrophy, characterized by layers of atrophic fibers at 
the periphery of the fascicles, often with perivascu-
lar infiltrates, is diagnostic of dermatomyositis even 
without skin manifestations 1-5, 24,25,26;
b) in anti-synthetase syndrome-Overlap Myositis the 
histology may overlap with that of DM but this entity 
predominantly affects the perimysium with necrotiz-
ing features of the perimysial and perifascicular areas 
along with actin myonuclear inclusions 1,16,17,25,26;
c) in polymyositis there is inflammation perivascularly 
and in multiple foci within the endomysium consist-
ing predominantly of CD8+ T cells invading healthy, 
non-necrotic, muscle fibers expressing MHC-I an-
tigen (normal muscle fibers do not express MHC-I 
antigen) 1-5.
 The MHC/CD8 complex is useful to confirm the 
diagnosis and exclude disorders with non-immune 
inflammation, as seen in some muscular dystro-
phies 1-5,17,25;
d) in Inclusion Body Myositis (IBM), in addition to the 
same inflammatory pattern described for PM, there 
are chronic myopathic changes with increased con-
nective tissue and fiber-size variability; autophagic 
vacuoles with bluish-red material “ragged-red” or 
cytochrome oxidase–negative fibers due to abnormal 
mitochondria; and congophilic amyloid deposits next 
to the vacuoles best visualized with crystal violet or 
fluorescent optics  1-5,17,18, 20,21. In up to 30% of IBM 
patients with the typical clinical IBM- phenotype, 
the biopsy does not show vacuoles or amyloid de-
posits but only inflammation, leading to erroneous 
diagnosis of polymyositis  1,17. Such patients have 
clinical IBM diagnosed on clinicopathologic correla-
tions 1,17,27; 
e) in necrotizing autoimmune myositis there are abun-
dant necrotic fibers invaded or surrounded by 
macrophages. Lymphocytic infiltrates are sparse 
and MHC-I upregulation mostly in the necrotic fi-
bers1-5,17,25. In a number of patients, the muscle biop-
sies show deposition of complement on blood vessels 
and, as expected, on necrotic fibers. Up to 65% of the 





Directed against nuclear RNAs or cytoplasmic an-
tigens, autoantibodies are detected in up to 75% of all 
IM patients depending on methodology 1. Although their 
pathogenic role is unclear, some antibodies appear specif-
ic for distinct clinical phenotypes. They include: 
a) anti-aminoacyl-tRNA synthetases, detected in 20-
30% of the patients 1,11,28,29. Among the eight different 
anti-synthetases, the antibodies directed against the 
histidyl-transfer RNA synthetase (anti-Jo-1), is the 
most common accounting for 75% of all anti-syn-
thetases and defines the “anti-synthetase- syndrome” 
described above; 
b) necrotizing autoimmune myositis-specific antibodies, 
against the translational transport protein SRP (Sig-
nal Recognition Particle) or against a 100-kd auto-
antigen identified as HMGCR (3hydroxy3-methyl-
glutaryl-coenzyme A reductase). Because HMGCR 
is the pharmacological target of statins  1,11-14, these 
antibodies have been thought to be associated with 
a prior statin use. These antibodies however are 
more often seen in statin-naive patients, and they are 
detected in up to 65% of all NAM cases from any 
cause 1,13,17. Most importantly, anti-HMGCR may be 
more often associated with malignancies rather than 
statins. They are disease markers and, contrary to 
some publications, they do not have a pathogenic role 
as explained below;
c) dermatomyositis-associated antibodies that include: 
i) Mi-2, highlighting the typical skin lesions; ii) mel-
anoma differentiation–associated protein-5 (MDA-5) 
mostly connected with amyopathic dermatomyositis 
or interstitial lung disease 1,30; and iii) transcriptional 
intermediary factor-1 (TIF-1) and nuclear matrix pro-
tein NXP-2, highly connected with cancer-associated 
adult DM 30; and 
d) anti-cytosolic 5’-nucleotidase- 1A (cN1A), detected 
in 33-51% of IBM patients 31. These antibodies have 
no pathogenic significance, and they can be also seen 
in patients with other types of myositis or rheumatic 
diseases. Their presence in IBM highlights however 
the immune dysregulation and B-cell activation. 
Triggering factors and 
associations 
Malignancies
Two IM subtypes are associated with malignancies, 
DM and NAM. In DM with malignancy a common anti-
body is the one against transcriptional intermediary fac-
tor-1 (TIF-1), while in NAM antibodies against HMGCR, 
especially in patients above the age of 50, are most fre-
quent. Among 349 patients with IM, 75 (21%) had cancer 
manifested usually within a year; among those patients, 
48% had DM with anti-TIF-1 antibodies and the other 
half had NAM with HMGCR 13.
Immune check-point inhibitors (ICPI’s)
An increasing number of patients with advanced ma-
lignancies treated with ICPI’s can develop immune-related 
neurological complications including inflammatory my-
opathies 32,33. The neurological events can evolve rapidly, 
necessitating the need for vigilance at all stages of treat-
ments, even after completion, because early immunother-
apeutic interventions with steroids and IVIg are effec-
tive. The main ICPIs currently on the market are directed 
against a) CTLA-4: Ipilimumab; b) PD-1: Pembrolizumab 
and Nivolumab; and c) PD-L1: Atezollizumab, Avelumab, 
and Durvalumab. The process by which ICPI’s trigger au-
toimmunity has been discussed elsewhere  32. Briefly, tu-
mors, like other antigen presenting cells, express on their 
cell surface the inhibitory ligands PD-L1/PDL-2 and B7-1/
B7-2 which are respectively engaged with PD-1 and CT-
LA-4 on T cells, downregulating T cell responses. These 
receptor/ligand interactions essentially act as an off switch, 
like “telling the T cells to leave the tumor cells alone” so 
T cells do not attack the tumor3 2. The ICPI’s prevent the 
CTLA-4 or PD-1 from binding to their respective receptors 
CD80/86 and PDL-1 and, by doing so, inhibit the inher-
ent “inhibitory” costimulatory interactions between T cells 
and tumor cells, resulting in positive signals. What ICPI’s 
essentially do is turning the switch back on resulting in pos-
itive costimulation and strong cell activation, like taking 
the brakes off the immune system 32. This blockade allows 
the T cells to kill tumor cells, but at the same time the re-
sulting enhanced co-stimulation causes an uncontrolled T 
cell activation that disrupts immune tolerance resulting in 
immune-related events against muscle. 
Among all the inflammatory myopathy subtypes, the 
most frequent autoimmune myopathies triggered by pem-
brolizumab, ipilimumab and nivolumab are DM and es-
pecially NAM. In some patients, NAM may co-exist with 
myasthenia gravis presenting with head drop, proximal 
muscle weakness, myalgia, dyspnea, ophthalmoparesis 
or bulbar weakness. Among 654 patients receiving IC-
PI’s (pembrolizumab: 389; nivolumab: 264; both: 1), 5 on 
pembrolizumab had biopsy proven myopathies (2 NAM, 1 
dermatomyositis, and 2 nonspecific myopathy) 33. Patients 
respond to steroids and IVIg especially if treated promptly. 
Viruses, including SARS-CoV-2
Among potential triggers, except of the Immune 
checkpoint inhibitors discussed above, viruses have 
clearly the potential to break tolerance and trigger an im-
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mune inflammatory myopathy. Although IM have been 
seen during or after a viral infection, attempts to amplify 
viruses from the muscles, including coxsackieviruses, in-
fluenza, paramyxoviruses, mumps, cytomegalovirus and 
Epstein-Barr virus, have failed 1-5. The best studied viral 
connection until now has been with retroviruses. Patients 
infected with HIV or human-T-cell-lymphotropic virus-I 
develop polymyositis or inclusion-body myositis  1-3, 34-35 
with retroviral antigens detected not within the muscle 
parenchyma but within some endomysial macrophages 
(Trojan-horse mode). The autoinvasive T cells are how-
ever clonally driven and some are retroviral-specific 35. 
During the present COVID-19 pandemic, there is 
evidence that more than 10% of COVID-19-infected 
patients develop myopathic symptoms with myalgia, 
weakness and elevated CK sometimes at very high CK 
levels >  10,000 suggestive of Necrotizing Autoimmune 
Myositis (NAM) 36. Although COVID-19-associated my-
ositis has not yet been studied but only characterized as 
“skeletal muscle injury” or “rhabdomyolysis”, two just 
published cases suggest an autoimmune COVID-19-trig-
gered NAM as summarized 36. One, an 88-year old man 
from New York presented with acute bilateral thigh weak-
ness and inability to get up from the toilet, without fe-
ver or other systemic symptoms, and very high CK level 
(13,581 U/L) 36. He was found COVID-19-positive, given 
hydroxychloroquine and a week later his painful weak-
ness improved with CK reduction. The other, a 60-year-
old man from Wuhan had a 6-day history of fever, cough 
and COVID-19-positive pneumonia with normal strength 
and CK; seven days later, although systemically had im-
proved, his CRP doubled and developed painful muscle 
weakness with very high CK (11,842 U/L)  36. He was 
given IVIg and his strength improved while became 
COVID-19-negative. 
In a recent retrospective study, patients hospitalized 
for a flue also had elevated CK level as high as those seen 
in a large series of patients with COVID-19  37 confirm-
ing the long-term notion that hyperCKemia can frequent-
ly occur in sick patients with an acute viral illness  1-3. 
However, an acute onset of severe muscle weakness with 
increased inflammatory markers and very high CK lev-
els in the thousands, as noted in the two cases above, is 
highly suggestive of an autoimmune inflammatory my-
opathy within the spectrum of NAM triggered by the 
virus, similar to what we first reported with HIV early 
in that epidemic  35,36. Considering that very high CK 
level and painful muscle weakness were seen in 10% of 
COVID-19-positive patients 36, a potentially treatable au-
toimmune myopathy might have been likely overlooked. 
This notion however requires a great deal of caution be-
cause without muscle biopsy confirmation and antibody 
screening, the diagnosis of COVID-19-NAM remains 
still undocumented because myopathic symptoms in a se-
vere systemic viral disease are multifactorial 37. The need 
to study COVID-19 muscle invasion is therefore needed 
and will be highly interesting because ACE2, the SARS-
CoV receptor, is reportedly expressed in skeletal muscle 
[summarized in 37]. If this is confirmed, COVID-19 may 
represent the first virus directly capable of infecting mus-
cle fibers. None of the viruses implicated as possible my-
ositis triggers has been shown to directly infect the mus-
cle fiber and our molecular studies have so far failed to 
detect any of them 38; instead, viruses induce an immune 
T cell-mediated with clonal expansion of viral-specific T 
cells, or macrophage-mediated, muscle fiber autoinvasion 
with abundant pro-inflammatory cytokines 1-3, 35,36. 
Statin exposure
A very small number of patients early on statin initi-
ation may experience transient myalgia, and some others 
transient CK elevation but no muscle weakness. In some 
patients, myalgia persists demonstrating statin intoler-
ance. Very rarely, patients may develop rhabdomyolysis 
soon after statin initiation. The implication however that 
chronic statin administration can, all of a sudden, trigger 
“ statin-myopathy” in the form of NAM 11,14 with antibod-
ies against HMGCR, a ubiquitous and non-muscle-spe-
cific antigen within the endoplasmic reticulum, has never 
been substantiated. Statins can upregulate HMGCR in 
cultured cells in vitro, and HMGCR is the target of action 
of statins, but studies from many centers throughout the 
world have consistently shown that anti-HMGCR autoan-
tibodies are more often seen in statin-naïve NAM patients 
and more often connected with cancer 13,39,40. Since NAM 
is now the commonest inflammatory myopathy and more 
than 25% of Americans above 40 years take statins, the 
association between statins and NAM is likely a chance 
phenomenon  1,17,41,42. Some authors correctly proposed 
that the term “statin myopathy” should not be used  40 
because only a minority of NAM patients had statin ex-
posure and, even in those patients, NAM appears many 
years after statin initiation making a causative role dubi-
ous if not impossible. 
Immunopathogenesis
Although the causes of inflammatory myopathies are 
unknown, an autoimmune pathogenesis is strongly impli-
cated, and seems to be specific for each subset. 
Dermatomyositis
In DM, early activation of complement C5b-9 mem-
branolytic-attack-complex is deposited on the endothelial 
cells 1-5,43, leading to capillary necrosis, reduction of endo-
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mysial capillaries, ischemia, and muscle-fiber destruction 
resembling microinfarcts  1-5; the remaining capillaries 
have dilated lumens to compensate for the ischemia  1-5. 
The residual perifascicular atrophy reflects the endofas-
cicular hypoperfusion, which is most prominent at the 
periphery of the fascicles. The membrane attack complex 
activation is triggered by binding of C1q to endothelial 
cells and releases proinflammatory cytokines, upregulates 
the adhesion molecules on endothelial cells, and facili-
tates the migration of activated lymphocytes including 
B cells, CD4+T cells and plasmacytoid-dendritic cells to 
perimysial and endomysial spaces. Innate immunity also 
plays a role based on increased expression of type-I inter-
feron-inducible proteins in the perifascicular regions  44; 
this effect appears secondary to ischemic damage which 
is probably sensed by the retinoic acid-inducible gene-1 
signaling leading to auto-amplification of local inflamma-
tion by activating β-interferon and MHC-1 45.
Necrotizing autoimmune myositis and the misconception 
of statin association or pathogenicity of antibody 
markers
Within the necrotic fibers of NAM, there are macro-
phages, MHC-I expression and deposition of complement; 
these findings have been loosely interpreted to suggest 
that in NAM there is complement- mediated cytotoxicity 
and the recruitment of macrophages invading the muscle 
fibers represent an antibody-dependent cell-mediated cy-
totoxicity (ADCC) process 11,14,46. There is no convincing 
evidence however supporting a pathogenic role of these 
antibodies in causing or triggering muscle fiber necrosis 
via an ADCC mechanism 41,42. Both, SRP and HMGCR 
antibodies, are against ubiquitous and non-muscle-specif-
ic antigens firmly localized in the endoplasmic reticulum 
and there is no explanation how antibodies against such 
cytoplasmic targets can selectively cause muscle fiber 
cell necrosis, as discussed 41. Further, MHC-1-expression 
and C5b-9 complement deposits are always observed in 
necrotic and regenerating fibers from any cause, such as 
commonly in muscular dystrophies  47,48, and lack speci-
ficity for NAM. Classic work of AG Engel et al dictates 
that all necrotic fibers in non-immune myopathies, such 
as muscular dystrophies, unambiguously activate com-
plement which in turn stimulates cellular infiltrates and 
macrophages  47,48. Further, claims that these antibodies 
can cause muscle fiber atrophy or affect regeneration in 
vitro49 are irrelevant to the cause of NAM where a macro-
phage-mediated muscle fiber necrosis causes devastating 
muscle destruction, not muscle fiber atrophy. Although 
not pathogenic, anti-SRP and anti-HMGCR antibodies 
remain important disease markers of diagnostic value be-
cause they are detected in up to 65% of NAM patients 1. 
Polymyositis and Inclusion-Body Myositis
In PM and IBM, CD8+cytotoxic T cells surround and 
invade healthy, non-necrotic muscle fibers that aberrantly 
express MHC-I  1-3,50-53. MHC-I expression, absent from 
the sarcolemma of normal muscle fibers, is probably 
induced by cytokines secreted by activated T cells. The 
CD8/MHC-I complex is characteristic of polymyositis 
and inclusion-body myositis and its detection aids in con-
firming the histologic diagnosis 2-5,50-53. The CD8+ T cells 
contain perforin granules directed towards the surface 
of the muscle fibers, resulting in myonecrosis upon re-
lease 54,55. Analysis of T-cell receptor molecules expressed 
by the infiltrating CD8+ T cells reveals clonal expansion 
of T-cell receptor chains and conserved sequences in 
the antigen-binding region, suggesting an antigen-driv-
en T-cell response  56-58. This is further supported by the 
expression of co-stimulatory molecules and upregulation 
of adhesion molecules, chemokines, and cytokines  59-61. 
Chemokines and cytokines, including interleukin-6, 8,10, 
monocyte chemoattractant protein 1, macrophage inflam-
matory protein 1a (MIP-1a), or IP-10 and its receptors, 
are expressed in the endomysial inflammatory cells and 
the neighboring extracellular matrix and may enhance 
leukocyte recruitment, trafficking and activation  62. Ad-
hesion of lymphocytes to muscle may be facilitated by 
metalloproteinases, which are expressed on the autoin-
vasive CD8+ T cells and make cell-to-cell contact with 
muscle fibers 1,17,63,64. There is also B-cell activation, most 
prominent in IBM 65 as supported by the presence of an-
ti-cytoplasmic 5’-nucleotidase 1A (cN1A; NT5C1A) au-
toantibodies directed against the cN1A nuclear protein 
involved in RNA processing 31. These antibodies are not 
however pathogenic or IBM-specific but simply denote 
the autoimmune dysregulation in IBM muscles. Plasma 
cells and myeloid dendritic cells, potent antigen-present-
ing cells, are also seen among the endomysial infiltrates 
of patients with PM, DM, and IBM  66 but their signifi-
cance is still unknown. 
Non-immune factors in Inclusion Body Myositis and 
cross-talk between inflammation degeneration and 
muscle autophagy
Inclusion-body myositis is a complex disorder because, 
in addition to the afore-mentioned autoimmunity, there 
co-exists an important degenerative component, highlight-
ed by the presence of congophilic amyloid deposits within 
some fibers 18,20,66,67. Similar to Alzheimer’s disease, these 
deposits immunoreact against amyloid precursor protein 
(APP), β-amyloid, apolipoprotein-E, α-synuclein, preseni-
lin, ubiquitin, and phosphorylated-tau attesting to protein 
aggregation 18,20,66. Immunostaining for the ubiquitin or tau 
components, TDP43 and p62, has been even advocated as 
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diagnostic markers 1,18,67. It remains however unclear, how 
these proteinacious aggregates, which are also seen in oth-
er vacuolar myopathies, induce an inflammatory myopathy 
and what triggers disease, inflammation or protein aggre-
gation 1,20. Laser microdissection of T-cell-invaded fibers, 
compared to non-invaded or vacuolated ones, has revealed 
differential upregulation of inflammatory signaling such 
as interferon-γ-receptor  68. Compelling evidence suggests 
that aging, abnormal proteostasis (the network controlling 
proteins) 1,28,20, cell stress induced by MHC-1 or nitric ox-
ide, long-standing inflammation and proinflammatory cy-
tokines like interferon-γ and IL1-β 69-70, may cumulatively 
trigger or enhance degeneration leading to further accumu-
lation of stressor molecules and misfolded proteins 1,69-71.
Treatment of DM, PM and NAM 
(Tab. I) 
Oral prednisone 1 mg/kg, or up to 100 mg per day, 
as a single daily dose is the first-line drug based on expe-
rience, but not controlled trials 1-6,17,72,73. Some clinicians 
prefer adding an immunosuppressant from the outset. 
In patients with severe or rapidly worsening disease, 
intravenous methylprednisolone 1  gm/kg for 3-5 days 
is preferable before starting oral glucocorticoids. After 
3-4 weeks, prednisone is tapered as dictated by the pa-
tient’s response, preferably by switching the daily dose to 
alternate-days 1-3. If by then objective signs of increased 
strength and activities in daily living are absent, taper-
ing is accelerated to start the next in-line agent. A tac-
tical error is the practice of “chasing” the CK level as a 
sign of response, especially in patients reporting a sense 
of “feeling better” but not necessarily stronger. When the 
strength improves, the serum CK drops, but fall in CK 
alone is not a sign of improvement 1-3. 
In glucocorticoid-responsive patients, azathioprine, 
mycophenolate mofetil, methotrexate or cyclosporine are 
empirically used for “steroid-sparing”  1-3, 17,72,73. When 
Table I. A step-by step approach in the treatment of inflammatory myopathies: 2020 and beyond.
Dermatomyosits (DM) 1-3,72-83
1. High-dose prednisone (oral or intermittent intravenous in acute cases)
2. In steroid-responsive patients add an immunosuppressant [mycophenolate, (most preferable) azathioprine, or 
methotrexate]
3. High-dose intravenous immunoglobulin (IVIg) if steps 1-2 fail
4. Rituximab, if IVIg is not sufficiently effective
5. Consider new biologics including eculizumab, other anti-B cell agents or JAK inhibitors
6. Most promising future: anti-complement agents such as eculizumab, ravulizumab (ultomiris), zilucoplan
Polymyositis (PM) 1-3,72-83
1. High-dose prednisone (oral or intermittent intravenous in acute cases)
2. In steroid-responsive patients add an immunosuppressant [mycophenolate, (most preferable) azathioprine, or 
methotrexate]
3. High-dose intravenous immunoglobulin (IVIg), if steps 1-2 fail
4. Rituximab, if IVIg is not sufficiently effective
5. If above unsatisfactory, reconsider the diagnosis and explore it with a new muscle biopsy
Necrotizing Autoimmune Myositis (NAM) 1-3,72-83
1. High-dose prednisone (intravenously 1g/daily for 5 days may be needed in acute cases)
2. High-dose intravenous immunoglobulin (IVIg) 
3. Rituximab, if IVIg not sufficiently effective
4. Consider new biologics, including eculizumab, other anti-B cell agents or JAK inhibitors
5. Most promising future: anti-complement agents, such as eculizumab, ravulizumab (ultomiris), zilucoplan
Anti-synthetase syndrome-Overlap Myositis (Anti-SS-OM) 1-3,72-83
1. High-dose prednisone (oral or intermittent intravenous in acute cases)
2. In steroid-responsive patients add an immunosuppressant [mycophenolate, (most preferable) azathioprine, or 
methotrexate]
3. High-dose intravenous immunoglobulin (IVIg) if steps 1-2 fail
4. Rituximab, if IVIg is not sufficiently effective
5. If interstitial lung disease, may also consider cyclophosphamide
Inclusion Body Myositis 1-3,84-92
1. Physical therapy; CoQ10; encourage participation in a controlled study
2. If dysphagia is prominent, IVIg
3. All trials with immunosuppressants, immunomodulating agents, muscle growth factors TGF-β inhibitors have 
failed. Among them, most promising was alemtuzumab in an uncontrolled study
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interstitial lung disease co-exists, cyclophosphamide or 
tacrolimus may be helpful  74. When glucocorticoids fail 
to induce remission or in rapidly progressive cases, in-
travenous immunoglobulin (IVIg) 2  gm/kg is appropri-
ate  1-3;69,70,73. In a double-blind study, IVIg was effective 
in refractory dermatomyositis 75; monthly infusions may 
be required to maintain remission. In open-label trials, 
IVIg also seems effective in polymyositis and necrotizing 
autoimmune myositis1-3,17,75. Subcutaneous Ig appears to 
sustain remission (Tab. I) 76. 
If glucocorticoids and IVIg have not helped, the di-
agnosis should be revisited, and a repeat muscle biopsy 
might be considered. If the diagnosis is re-confirmed, 
biologics approved for other immune diseases are fur-
ther options  1-3,70,73. Among those, the first is rituximab 
(anti-CD20 antibody), which at 2  gm (divided in two 
bi-weekly infusions) seems effective in several dermato-
myositis, polymyositis, and necrotizing autoimmune my-
ositis patients. A placebo-controlled study in 200 patients 
however, did not meet the primary end-point largely be-
cause of study design; although at week 8 there was no dif-
ference between placebo and rituximab, at week 44 when 
all patients had received rituximab, 83% met the defini-
tion of improvement  77,78. Patients with anti-Jo-1, Mi-2, 
or anti-SRP antibodies are also likely to respond  78,79,80. 
TNF inhibitors (infliximab, adalimumab, etanercept) are 
ineffective and may worsen or trigger disease 1,17. Tocili-
zumab and IL-1b inhibitors may be of help in small case 
series  81,82. Among the new biologics, anti-complement 
C5 (eculizumab), should be very promising especially in 
dermatomyositis where complement plays a major role 
in microangiopathy and muscle fiber necrosis. Eculizum-
ab may be also effective in NAM but controlled studies 
have not been done. Overall, the long-term outcome of 
treatment for inflammatory myopathies has substantially 
improved, with a 10-year survival at > 90% 83. A step-by-
step therapeutic approach in all IM subsets is provided in 
Table I.
Immunotherapies for IM during COVID-19
Patients with IM have been justifiably concerned as 
to whether their disease status adds an additional risk 
placing them into an “immunosuppressed or immuno-
compromised” category. As discussed previously 36, there 
is no evidence that the inflammatory myopathy itself 
makes them more susceptible to COVID-19 or the im-
munosuppressive therapies they are receiving have such a 
potential. If clinically stable and not lymphopenic, there 
is no data-driven reasons to change anything and disturb 
clinical stability. For patients on monthly IVIg, there may 
be even a theoretical advantage that IVIg offers additional 
protection due to natural autoantibodies 36; if IVIg is not 
infused as home-infusion, switching to self-administered 
subcutaneous IgG might be an option to diminish expo-
sure. For patients on rituximab, the infusion intervals can 
be prolonged to more than 6 months, because both, B-cell 
reduction and clinical benefit, can persist longer 36. 
Treatment of Inclusion-Body 
Myositis
Because of T-cell-mediated cytotoxicity and the en-
hancement of amyloid aggregates by pro-inflammatory 
cytokines as outlined earlier, immunosuppressive agents 
have been tried in IBM but all failed probably because 
the disease starts long before patients seek medical ad-
vice, when the degenerative cascade is already advanced 
and inflammatory mediators have enhanced degeneration 
and autophagy  1-3,17,84-86. Glucocorticoids, methotrexate, 
cyclosporine, azathioprine or mycophenolate are inef-
fective and, although some patients initially experience 
mild improvements, there is no long-term benefit  1,17,84. 
IVIg is ineffective in controlled trials but may transiently 
help some patients, especially those with life-threatening 
dysphagia where is the treatment of choice based on sta-
tistically significant changes in the controlled trial  87,88. 
Alemtuzumab may provide short-term stabilization 89 but 
a controlled study is needed. Anti- IL1-receptor (Anak-
inra) 90 and IL1 receptor antagonist (Ilaris) also failed 91. 
Trials targeting muscle-inhibiting TGF-β molecules or 
muscle growth factors are also disappointing and dou-
bleblind studies have been clearly negative92. Although 
life expectancy seems normal, most patients with end-
stage disease require assistive devices such as cane, walk-
er, or wheelchair 22. Dysphagia can be life threatening if 
IVIg has not helped. 
Evolution of the IM field in the 
context of the Mediterranean 
Society of Myology (MSM) with a 
personal tribute to G. Nigro
Inflammatory myopathies have been discovered and 
subsequently studied by Neurology scholars with exper-
tise in neuromuscular pathology fostering progress in 
muscle immunopathology, disease recognition, subset 
subtyping and pathogenesis. Over the last 30  years the 
very best minds and Neurology scholars in this field with 
leaders like W King Engel, Valerie Askanas, Andrew En-
gel, George Karpati, Victor Dubovitz and many others 
from USA, Italy, France, Australia, Israel etc. have par-
ticipated on a regular basis in the MSM meetings. I have 
had the chance to be there every year almost since the 
creation of the MSM and have hosted two such events in 
Greece, one in Corfu and another one in Athens. Writing 
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this piece in the memory of Giovani Nigro brings back a 
blend of unique pleasantries of good science and humour 
in a relaxing and friendly atmosphere of picturesque en-
vironments and scholarly, formal, and informal, discus-
sions about inflammatory myopathies. Being honoured 
by Giovanni in his unique style at the gala dinner among 
the best of friends and neuromuscular colleagues was the 
epitomy of the MSM that I will never forget. 
This opportunity in honouring the memory of 
Giovanni Nigro and the unique meetings he has organized 
and overseen, is also an introspective on the future of the 
IM field as it is now moving from the neuromuscular cli-
nicians/scientists that splendidly served it for years and 
advanced the field, to other subspecialties with different 
training backgrounds. We have all witnessed the last few 
years that neurologists with muscle pathology and immu-
nopathology training are becoming increasingly scarce as 
very few of us continue to keep an active muscle pathology 
laboratory. Muscle biopsies are mostly performed now by 
surgeons, read by general pathologists either on paraffin 
sections with just the very basic – if any – immunopathol-
ogy or enzyme histochemistry stains on fresh-frozen sec-
tions, and without knowledge of the clinical neuromuscu-
lar evaluation. The lack of clinicopathologic correlation, 
a fundamental principle of a neuromuscular neurologist 
for the diagnosis of myopathies, as pioneered by WK En-
gel and taught all of us, may be impacting on the identifi-
cation of the correct inflammatory myopathy subtype and 
the distinction from dystrophies. We had been proud of 
our unique expertise to precisely assess and quantify the 
patient’s muscle strength, being aware on how best to dis-
tinguish the contribution of functional weakness or pains 
from true muscle weakness, and bring this to diagnostic 
fruition by personally performing muscle biopsy, select-
ing the muscle to biopsy, looking at the slides and, after 
combining clinical with histology, initiate proper thera-
py. Concurrently, research on expanding the diagnostic 
muscle histopathology, immunopathology or molecular 
muscle pathology had flourished. Today, most clinicians 
involved in the diagnosis and care of patients with IM are 
of different subspecialties with different training back-
grounds, such as rheumatologists, rheumatoneurologists 
or neurologists/elctromyographers. The prior focus on 
myopathology and molecular muscle immunopathology 
is slowly being shifted to serology, circulating humoral 
factors and antibodies, and muscle imaging. Whether will 
prove more fruitful remains to be seen.
 Serving for more than 40 years as head of Neuro-
muscular service with still a fully functioning laboratory 
and having trained more than a hundred neuromuscular 
fellows around the world, I am also witnessing the direc-
tional shift of our neuromuscular trainees who are mostly 
centered around electromyography. We are not however 
to blame; it is economics that has prevented the main-
tenance of active neuromuscular pathology laboratories 
in many Universities. As a result, previously flourishing 
regional myology meetings, such as the MSM under Dr 
Giovanni Nigro’s leadership, have vanished as if there is 
not need to have them; electromyographers go to electro-
physiology meetings, rheumatologists to rheumatology 
meetings and general neurologists to neurology meetings. 
Writing this in honouring of Giovanni Nigro’ mem-
ory, I remain with the pleasant memories of blending the 
many years of myology progress with innovative dis-
cussions about culture and civilization with stimulating 
leaders in the clinical and basic science of muscle dis-
eases. These unforgettable memories in the middle of the 
COVID-19 pandemic bring me back to the sad reality 
that the wonderful Giovanni Nigro’s era of the MSM may 
never return; yet at the same time, as the sun comes after 
a storm, these memories also bring shining hopes on how 
Giovanni’s legacy will build a bright future for our field. 
After the COVID-19 pandemic ends, we should be all 
armed with enthusiasm, determination and organization-
al to re-build the society from where it started, teach the 
new generation of neuromuscular experts what we have 
all learnt, and provide them with the stimulus on how best 
to combine the excellence in the clinic with  histopathol-
ogy,  immunology, immungenetics and molecular biolo-
gy to advance the filed towards effective target-specific 
therapies. Afterall, the advances in molecular science and 
means of communication are on our side. This will be 
Giovani’s best legacy.
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